Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7633797 | 0.77 | DRD2 (0.43) | DRD2DRD1CYP19A1PDK2HTR1A | |
| SCHEMBL5187232 | 0.74 | DRD2 (0.39) | DRD2DRD1CYP19A1PDK2HTR1A | |
| SCHEMBL13245792 | 0.74 | DRD2 (0.42) | DRD2DRD1TBXAS1 | |
| SCHEMBL27932286 | 0.73 | DRD2 (0.41) | DRD2DRD1CYP19A1PDK2HTR1A | |
| SCHEMBL17781829 | 0.73 | DRD2 (0.41) | DRD2DRD1CYP19A1SLC6A4TBXAS1 | |
| SCHEMBL14395237 | 0.67 | CHRNB2 (0.44) | DRD2DRD1CYP2D6 | |
| SCHEMBL359803 | 0.67 | CHRNB2 (0.44) | DRD2DRD1CYP2D6 | |
| SCHEMBL29568322 | 0.67 | CHRNB2 (0.44) | DRD2DRD1CYP2D6 | |
| SCHEMBL17760134 | 0.67 | HTR2C (0.42) | DRD2DRD1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL30309386 | 0.67 | DRD2 (0.36) | DRD2DRD1CYP19A1PDK2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231592-A1 | SUBSTITUTED 2-(4-HETEROCYCLYLBENZYL)ISOINDOLIN-1-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231592-A1 | SUBSTITUTED 2-(4-HETEROCYCLYLBENZYL)ISOINDOLIN-1-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM5 | DRD2 78/4885DRD1 145/4885CYP19A1 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.